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ABSTRACT
Methicillin-resistant Staphylococcus aureus (MRSA), both hospital-acquired and community-acquired, is a
dangerous pathogen that is involved in an increasing number of serious infections with high risk for
morbidity and mortality. Community-acquired MRSA strains have epidemic potential and can be
particularly virulent. Vancomycin has been the standard hospital treatment for the past 40 years, but
vancomycin-resistant isolates of S. aureus have emerged in the USA, and vancomycin-intermediate
isolates are increasingly being reported worldwide. New antimicrobial agents with activity against
multidrug-resistant S. aureus and other resistant pathogens are urgently needed. Despite great strides,
further advances in our understanding of the molecular and biochemical mechanisms responsible for
antimicrobial resistance are still required. Several agents have been recently approved for the treatment
of serious Gram-positive infections, including linezolid, daptomycin, and tigecycline. The novel
investigational cephalosporin, ceftobiprole, is one of the ﬁrst penicillinase-resistant agents to target
penicillin-binding protein 2a (or PBP2a), an acquired PBP with low b-lactam-afﬁnity that confers
intrinsic b-lactam resistance to S. aureus and other staphylococci. This mechanism of PBP binding,
including inhibition of PBP2a, confers broad-spectrum activity against clinically important Gram-
negative and Gram-positive pathogens, including MRSA. Phase III clinical trials comparing ceftobiprole
with vancomycin alone and in combination with ceftazidime for the treatment of complicated skin and
skin structure infections showed ceftobiprole to have efﬁcacy similar to the efﬁcacy of these comparators
as evidenced by non-inferior clinical cure and microbiological eradication rates.
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INTRODUCTION
Clinicians are faced with patients who have
virulent, difﬁcult-to-treat infections caused by
antimicrobial-resistant pathogens on an increas-
ingly frequent basis, in both the inpatient and
outpatient settings. The extent of this challenge is
shown by ﬁndings from the Surveillance Net-
work-USA from 300 microbiology laboratories
across the USA between 1998 and March 2005.
From a total of over three million bacterial isolates
from inpatients, Staphylococcus aureus was the
most commonly observed species, with a
prevalence of 18.8% [1]. Infection with S. aureus
in hospitalised patients has been associated with a
ﬁve-fold higher rate of in-hospital all-cause mor-
tality, a three-fold longer length of stay, and a
three-fold higher total hospital expenditure as
compared with that for uninfected patients [2].
S. aureus has proven to be adept at developing
resistance to antimicrobial agents. Methicillin
resistance is only the most recent twist in the
road towards b-lactam resistance that began
decades ago. Strains of S. aureus resistant to
semi-synthetic penicillins were already recogni-
sed as problematic within the ﬁrst few years of
the introduction of these agents [3,4].
The challenge of ﬁnding new chemotherapeutic
agents to treat infections with antimicrobial-resis-
tant S. aureus is not likely to abate. Methicillin-
resistant S. aureus (MRSA) has become endemic in
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the USA and continues to grow in prevalence in
Europe and other areas of the world [5]. Further-
more, the clinical usefulness of vancomycin is
expected to diminish because of the emergence of
vancomycin-resistant S. aureus (VRSA) and
vancomycin-intermediate S. aureus (VISA) [6,7].
Antimicrobial resistance in S. aureus is responsi-
ble for the poor clinical outcomes associated with
this pathogen; infection-attributable mortality is
twice as great with MRSA as with methicillin-
susceptible S. aureus (MSSA) [8].
The purpose of this article is to review the
knowledge gained over the past several years
with respect to mechanisms of resistance of
S. aureus to b-lactams at the molecular, biochem-
ical and structural biological levels. The article
will also discuss targets for development of new
anti-MRSA agents, with a focus on the novel
cephalosporin ceftobiprole, a b-lactam with
broad-spectrum activity that was designed to
directly overcome the prevalent mechanism of
methicillin resistance.
GENETIC ORIGIN OF METHICILLIN
RESISTANCE
Methicillin resistance is associated with the acqui-
sition of a particular resistance island called
SCCmec, where SCC stands for staphylococcal
cassette chromosome and mec for the genetic
element conferring resistance to methicillin [9].
SCCmec is an exogenous piece of DNA that may
vary between 15 and 60 kb and is absent from
methicillin-susceptible staphylococci. Its bound-
aries are demarcated by direct and inverted
repeats, which allow integration at a homologous
site into the chromosome. Critical genes of SCCmec
include the recombinases ccrA and ccrB, which can
mediatemobilisation of thewhole element, and the
mecA gene, which mediates b-lactam resistance
[10]. The mecA gene encodes for a particular
penicillin-binding protein (PBP) called PBP2a,
which has a very low afﬁnity for methicillin and
most other b-lactam drugs [11]. Hence, PBP2a is
responsible for the intrinsic resistance of MRSA to
almost all b-lactams (see below).
At least ﬁve types of SCCmec were discrimi-
nated on the basis of the structure of their ccrA–B
and mecA complexes [10,12,13]. These ﬁve types
are likely to mirror major original MRSA clones.
SCCmec types I, II and III were shown to belong
to hospital clones (Fig. 1) [14]. Types II and III
harbour multiple resistance determinants, have
relatively large sizes (35–60 kb), and are difﬁcult to
mobilise. Hence, they are stable. Recently, a fourth
and a ﬁfth type (type IV and type V, respectively)
of SCCmec have been identiﬁed as being typical of
community-acquired MRSA [13,15]. They are
Fig. 1. Structures of staphylococcal
cassette chromosome types based on
multiple-locus sequence typing.
Adapted with permission from
Okuma et al. [14].
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much smaller (c. 15 kb) than their hospital-related
congeners, do not carry multiple antibiotic resis-
tance genes, and may be easier to mobilise (Fig. 1)
[4,14]. The SCCmec types are often associated with
other elements in the same bacterium, including
the Panton–Valentine leukocidin toxin, which is
encoded by a virus, and multiple staphylococcal
exotoxin (set) genes, which are located on the mSab
pathogenicity island [16]. Together, these elements
may render the organism particularly ﬁt and
virulent.
It is unlikely that these particular community-
acquired MRSA strains have arisen from hospital
MRSA strains that permeated the community.
Instead, it is more probable that community-
acquired MRSA strains have emerged indepen-
dently, having acquired their SCCmec from
coagulase-negative staphylococcal donors [17],
and were able to evolve either because of the
widespread use of b-lactams, or because it pro-
vides another, as yet undetermined, advantage to
the bacterium. Thus, on the basis of the epidemi-
ology of MRSA infection, it has become important
to distinguish healthcare-associated MRSA
strains, which are multiresistant and carry the
large and more evolved versions of SCCmec, from
the genuine community-acquired MRSA strains,
which tend to be still susceptible to many
commonly used antibiotics (e.g., trimethoprim–
sulfamethoxazole) and carry the smaller and
possibly original forms of SCCmec [18,19].
LIMITATIONS OF CURRENT
ANTIMICROBIAL AGENTS
Although several other antimicrobial agents be-
sides methicillin and vancomycin have been used
to manage S. aureus infections, these agents all
have limitations for treating infections when
methicillin- or vancomycin-resistant S. aureus is
involved [20]. Multiresistance in nosocomial
MRSA strains and many strains of community-
acquired MRSA renders ﬂuoroquinolones, amino-
glycosides, erythromycin, and clindamycin useless
[21]. With the possible exception of clindamycin,
these agents are also ineffective against VRSA and
hetero-VISA. Other agents have limited activity
against speciﬁc resistant strains of S. aureus and
lack speciﬁc efﬁcacy characteristics that are neces-
sary for particular clinical indications. Rifampin,
with in-vitro activity against MRSA, has minimal
activity against VRSA and hetero-VISA, has been
associated with rapid development of resistance,
and is not recommended as monotherapy for
invasive infections. Trimethoprim–sulfamethox-
azole has activity against MRSA and VISA, but
clinical data on efﬁcacy in serious infections are
lacking and ⁄ or difﬁcult to interpret. Also, this
agent is not recommended as empirical therapy for
complicated skin and skin structure infections
(cSSSIs) if group A streptococci are suspected.
Tetracyclines, which have in-vitro activity against
community-acquired MRSA, are effective for skin
infections, but data on efﬁcacy for invasive disease
are lacking, and, like trimethoprim–sulfamethox-
azole, tetracyclines are not recommendedas empir-
ical therapy if group A streptococci are suspected
[20].
NEW NON-b -LACTAM DRUGS
ACTIVE AGAINST MRSA
During the last few decades, drug discovery has
not always kept up with the emergence of
antimicrobial resistance and the increasing need
for new agents with which to treat patients with
serious bacterial infections [22]. The ﬁrst antimi-
crobial drug classes were the sulphonamides,
introduced in 1935, and the penicillins, intro-
duced in 1941, and these were followed by three
other antimicrobial drug classes (cephalosporins,
aminoglycosides and chloranphenicol), which
became available in the 1940s. Development of
new antimicrobial drug classes reached a peak in
the 1950s with the introduction of six new classes
(tetracyclines, macrolides-lincosamides-strepto-
gramins, glycopeptides, rifamycins and nitroimi-
dazoles). Since then, successful research on and
development of new antimicrobial classes has
slowed, with only two new classes emerging in
the 1960s (quinolones and trimethoprim), and
then none until 2000, with the release of an
oxazolidinone, followed by a lipopeptide in 2003.
The state of antibiotic development is illustrated
by a survey in 2002 of clinical development
programmes. Although the total expenditure for
antimicrobial drug development of the ten largest
pharmaceutical companies has increased from
$21.9 billion in 1998 to $28.8 billion in 2002, an
increase of 31%, FDA approval of new antimi-
crobial agents has decreased by 56% over the last
20 years [23]. Likewise, the number of new anti-
bacterial drugs approved each year by the FDA
has decreased from 2.9 in the 1960s to 1.6 since
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2000 [24]. A number of reasons may explain this
worrisome situation, including low commercial
value of niche drugs that treat infections caused
by resistant pathogens, and increasing constraints
in designing appropriate clinical trials.
Despite the general paucity of research on and
development of antimicrobials as compared with
that for agents for other therapeutic areas, anti-
MRSA agents have received priority within anti-
microbial research. Many of these agents target
bacterial protein synthesis, some are directed
against the established target of peptidoglycan
synthesis, and a few are aimed at new drug
targets, including peptide deformylase. These are
brieﬂy summarised below.
Protein synthesis inhibitors
Oxazolidinones, macrolides–streptogramins–lin-
cosamides (MLSAB) and glycylcyclines are the
major molecule classes in this group. The oxazo-
lidinone linezolid is a narrow-spectrum anti-
Gram-positive compound. It prevents formation
of a 70S initiation complex by binding to the 50S
ribosomal subunit near the interface with the 30S
subunit [25]. This agent is bacteriostatic against
staphylococci [25] and has an MIC90 of 2 mg ⁄L
against MRSA [26]. Linezolid is approved in the
USA for the treatment of nosocomial pneumonia
due to MSSA, MRSA, and multidrug-resistant
Streptococcus pneumoniae, and cSSSIs (including
diabetic foot infections) caused by MSSA, MRSA,
Streptococcus pyogenes, or Streptococcus agalactiae
[25]. The MLSAB quinupristin (streptogramin B)–
dalfopristin (streptogramin A) also targets
primarily Gram-positive bacteria. Its two com-
pounds bind synergistically to the 50S subunit of
the bacterial ribosome, inhibiting protein synthe-
sis during both the early (quinupristin) and late
(dalfopristin) phases [27]. The drug combination
has an MIC90 of 1 mg ⁄L against MRSA and is
bactericidal against MLSB-susceptible isolates, but
only bacteriostatic against constitutively MLSB-
resistant strains [26]. This combination agent is
approved in the USA for the treatment of serious
or life-threatening infections caused by Enterococ-
cus faecium and for cSSSIs caused by MRSA [27].
The glycylcycline tigecycline is a modiﬁed tetra-
cycline that has a broad spectrum of antibacterial
activity. It inhibits protein synthesis by binding to
the 30S ribosomal subunit and blocking entry of
amino-acyl tRNA molecules into the A site of the
ribosome [28]. This agent is not affected by
ribosomal protection or drug efﬂux (the two
main tetracycline resistance mechanisms) [29].
Tigecycline is bacteriostatic against MRSA
(MIC90 0.5 mg ⁄L), has in-vitro activity against
VISA and VRSA (MIC90 £0.5 mg ⁄L), and is
approved in the USA for cSSSIs caused by MRSA,
and in the European Union for cSSSIs and com-
plicated intra-abdominal infections [28,30].
Transpeptidase ⁄ transglycosylase inhibitors
Two new glycopeptides, dalbavancin and tela-
vancin, target transpeptidase and transglyco-
sylase to inhibit peptidoglycan synthesis. Like
other glycopeptides, they are active only against
Gram-positive bacteria. The MIC90s of these
agents for MRSA are 0.125 mg ⁄L (dalbavancin)
and £1.0 mg ⁄L (telavancin, oritavancin) [31–33].
At present, neither of these agents has marketing
approval.
Plasma membrane integrity
The cyclic lipopeptide daptomycin acts by altering
the membrane ion ﬂux. It is bactericidal against
Gram-positive bacteria. It inhibits bacterial DNA
and RNA synthesis as well as protein and lipid
biosynthesis [34]. Daptomycin has an MIC90 of
2 mg ⁄L against MRSA [35]. Daptomycin is ap-
proved in the European Union for the treatment of
cSSSIs, right-sided endocarditis due to S. aureus,
and S. aureus bacteraemia associated with right-
sided endocarditis or cSSSIs [36], and in the USA
for MRSA and MSSA cSSSIs and bacteraemia,
including right-sided endocarditis [34].
Peptide deformylase inhibitors
Two peptide deformylase inhibitors, LBM415 and
BB-83698, have demonstrated bacteriostatic
effects on MRSA in vitro (MIC90 2 mg ⁄L for
LBM415 and 8 mg ⁄L for BB-83698) [37–39]. Deﬁn-
itive clinical evaluation with these compounds is
as yet unavailable.
THE RATIONALE FOR DEVELOPING
b -LACTAMS WITH IMPROVED PBP2A
AFFINITY
Intrinsic resistance of S. aureus to methicillin and
most otherb-lactams is conferredby78-kDaPBP2a,
Moreillon Treatment of Staphylococcus aureus infections 35
 2008 The Author
Journal Compilation European Society of Clinical Microbiology and Infectious Diseases, CMI, 14 (Suppl. 3), 32–41
which is the product of themecAgene [15,39]. PBPs
are membrane-bound enzymes with multiple
enzymatic functions, including transpeptidase
and transglycosylase activities necessary for bac-
terial cell-wall synthesis. The transpeptidase sites
of wild-type PBPs bind b-lactams with high afﬁn-
ity, resulting in inactivation of the bacterial enzy-
matic activity and inhibition of cell-wall synthesis
and cell growth. In contrast, PBP2a has a low
afﬁnity for b-lactam agents and remains active in
the presence of these agents [40–43].
However, the survival beneﬁt that PBP2a con-
fers to S. aureus by imparting resistance to meth-
icillin has some intrinsic drawbacks, providing
opportunities for drug development. First, it was
originally thought that PBP2a possessed both
transpeptidase and transglycosylase activity and
thus could carry out peptidoglycan assem-
bly—which requires both transpeptidase and
transglycosylase—independently of the S. aureus
wild-type PBPs. However, it turns out that PBP2a
has only transpeptidase activity and thus must
cooperate with the transglycosylase domain of
wild-type PBPs to assemble its cell wall (Fig. 2)
[44]. Moreover, only one of the four wild-type
PBPs of S. aureus possesses a transglycosylase
domain (i.e., class A PBP2), whereas the others
are pure transpeptidases (i.e., class B PBP1, PBP3,
and PBP4) that might also compete to use PBP2 as
a partner for transglycosylation. Thus, the activity
of PBP2a might be affected by the interaction of
other PBPs with wild-type PBP2.
Second, PBP2a can process only speciﬁc types
of cell-wall precursors, those that carry a penta-
glycine decoration attached to the position-3
lysine of their stem peptides [43]. The assembly
of this pentaglycine relies on the coordinated
activity of more than 40 auxiliary genes, including
the fem (factor essential for resistance to methicil-
lin) and aux (auxiliary) genes [45,46]. Mutations in
such genes have been associated with decreased
resistance to methicillin (Fig. 3). Serendipitous
alterations in any of these many determinants will
abrogate PBP2a activity.
Third, although the SCCmec elements carrying
the mecA genes are quite variable, the mecA gene
itself—and hence PBP2a—is highly conserved
[10,12,13]. Taken together, these elements indicate
that PBP2a-mediated b-lactam resistance is under
strong biological constraints. This assumption is
also supported by the difﬁculty in obtaining
PBP2a mutants with further decreased b-lactam
afﬁnity when MRSA strains are exposed to
b-lactams with improved PBP2a-binding ability,
and thus improved anti-MRSA activity [47].
Hence, the constraint of the system and wide
conservation of PBP2a among the studied isolates
paradoxically make low-afﬁnity PBP2a a highly
suitable target for drug-induced blockage.
ANTI-MRSA AGENTS: MECHANISM-
BASED INHIBITORS OF PBP2A
In theory, for a b-lactam agent to have activity
against MRSA, it must target PBP2a and must not
be vulnerable to hydrolysis by penicillinases.
Fig. 2. Model for cooperative functioning between peni-
cillin-binding protein (PBP)2a and wild-type PBP2 in
methicillin-resistant Staphylococcus aureus (MRSA). Rep-
rinted with permission from Pinho et al. [44]. In the
absence of b-lactam antibiotics (top panel), wild-type
PBP2 ensures both transpeptidase (TPase) and transgly-
cosylase (TGase) activities to insert new peptidoglycan
precursors into the walls. PBP2a is mostly inactive in this
condition [43]. In the presence of b-lactams (lower panel),
the TPase site of wild-type PBP2 becomes blocked, while
that of low-afﬁnity PBP2a remains free. Hence, PBP2a can
complement the b-lactam-inhibited TPase of wild-type
PBPs in the presence of antibiotics.
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Findings from preclinical studies of experimental
endocarditis provided support for this concept.
First, older b-lactams such as penicillin G, ampi-
cillin, amoxycillin and cefamandole were
efﬁcacious against infections caused by methicil-
lin-resistant strains that did not produce
penicillinase. Later, in the face of widespread
penicillinase-based resistance, their efﬁcacy was
maintainedby combining themwith apenicillinase
inhibitor [48–52]. Second, crystallography studies
have conﬁrmed interaction between the older
b-lactam agents and the active site of PBP2a [53,54].
Despite these positive ﬁndings in preclinical
studies, the strategy of using a combination of an
older b-lactam plus a penicillinase inhibitor was
not followed up with rigorous clinical studies, for
at least two reasons. First, administration of large
doses of the older molecules was needed, owing
to their relatively high MICs for MRSA and
difﬁcult optimisation of the penicillinase-inhibit-
ing dose (a necessary component, because most
MRSA strains produce penicillinases). Second,
glycopeptides were still uniformly active against
MRSA at this time [55].
Instead, the design of penicillinase-resistant
b-lactams with high afﬁnity for PBP2a was pur-
sued as a more promising approach. Investiga-
tional b-lactams with any activity against MRSA
were mainly found in the carbapenem and
cephem subclasses of cephalosporin b-lactams
(reviewed in [55]). The ﬁrst investigational anti-
MRSA b-lactam to show clinical efﬁcacy was
ceftobiprole [56].
Ceftobiprole is a semi-synthetic molecule that
varies from its cephem origin by alterations at the
C-3 and C-7 components of the basic cephem ring
(Fig. 4). These modiﬁcations increase its afﬁnity
for PBP2a through enhanced lipophilicity, and the
substitution C-7 (an aminothiazolyhydroxyimino
side chain) provides greater stability in the pres-
ence of penicillinases [55,57,58]. The solubility
issues resulting from the increased lipophilicity of
this compound were circumvented by synthesis
of the water-soluble prodrug, ceftobiprole medo-
caril [58].
CEFTOBIPROLE
In-vitro activity
The in-vitro activity proﬁle of ceftobiprole has
been found to be consistent with that of the
cephalosporin class, with bactericidal activity
against many Gram-positive and Gram-negative
species. In addition, ceftobiprole has been dem-
onstrated to be bactericidal against MRSA [59].
Fig. 3. The effects of mutations in fem genes on resistance
to methicillin in Staphylococcus aureus. Reprinted with
permission from Berger-Bachi [45]. Large bacterial popu-
lations (up to 109 CFU per plates; y-axis) were spread on
nutrient agar plates containing increasing concentrations
of methicillin (x-axis), and bacterial sub-populations grow-
ing on increased drug concentrations were determined.
Open squares–dotted line, susceptible parent strain; ﬁlled
squares–dotted line, heterogeneous MRSA; ﬁlled circles–
solid line, inactivated femA gene; ﬁlled squares–solid line,
inactivated femB gene; ﬁlled triangles–solid line, inacti-
vated femC gene; ﬁlled diamonds–solid line, inactivated
femD gene.
Fig. 4. Structures of the basic carbapenem ring, ceftobi-
prole medocaril, and ceftobiprole. Adapted with permis-
sion from Guignard et al. [55].
Moreillon Treatment of Staphylococcus aureus infections 37
 2008 The Author
Journal Compilation European Society of Clinical Microbiology and Infectious Diseases, CMI, 14 (Suppl. 3), 32–41
Data from a study comparing ceftobiprole in-
vitro activity against various Gram-positive and
Gram-negative isolates indicated a broad spec-
trum of antimicrobial activity [26]. The MICs of
ceftobiprole for clinically relevant Gram-positive
and Gram-negative pathogens are listed in
Table 1 [26,60]. Ceftobiprole, vancomycin and
linezolid were the only highly effective agents
against MRSA in this study (the other compara-
tors included teicoplanin, quinupristin–dalfopri-
stin, and ceftriaxone). The activity of ceftobiprole
against coagulase-negative staphylococci was
among the highest seen in this trial, with an
inhibitory rate >90%; the other agents with this
level of activity were vancomycin, linezolid, and
quinupristin–dalfopristin [26].
The activity of ceftobiprole against Enterococcus
faecalis was similar to that of ampicillin, penicillin,
and amoxycillin–clavulanic acid. Although cefto-
biprole activity against E. faecium was low, it was
similar to that of the other tested penicillins
against the remaining Enterococcus spp. [26].
Activity against Streptococcus spp. was particu-
larly high for ceftobiprole, with high susceptibil-
ity seen for penicillin-resistant S. pneumoniae,
penicillin-resistant viridans group streptococci,
and b-haemolytic streptococci [26].
Surveillance studies have generally shown cef-
tobiprole to match broad-spectrum cephalospo-
rins such as cefepime and ceftriaxone for potency
against Gram-negative bacteria, but to be more
active than these agents against Gram-positive
organisms. The potency of ceftobiprole for inhib-
iting Gram-negative pathogens is species-depen-
dent [60]. Although the in-vitro activity of this
agent against Gram-negative pathogens overall
does not reach that of imipenem and ciproﬂoxa-
cin, its potency is greater than that of cefepime
and cefozopran, and the latter two, along with
ceftobiprole, have sufﬁcient in-vitro activity to
indicate clinical utility [58,60].
Clinical development
The efﬁcacy of ceftobiprole has been assessed in
clinical trials for treatment of cSSSIs. Two com-
pleted, randomised, double-blind, active-con-
trolled, multicentre, multinational phase III
clinical trials have been completed. The ﬁrst trial
demonstrated that ceftobiprole was non-inferior
to the comparator vancomycin for clinical cure
and clinical relapse rates in adult patients with
cSSSIs due to Gram-positive pathogens (n = 784
for the intent-to-treat population). Non-inferiority
of ceftobiprole was also seen in the analysis of
overall microbiological eradication and microbio-
logical relapse rates. Sub-analysis of patients with
microbiologically conﬁrmed involvement of
S. aureus showed that clinical cure rates with
ceftobiprole for MRSA and MSSA were similar to
those for vancomycin and to the overall clinical
cure rate [61].
The second phase III trial enrolled 828 adult
patients with cSSSIs due to either Gram-positive
or Gram-negative pathogens. Patients with dia-
betic foot infections were also included. The data
demonstrated the non-inferiority of ceftobiprole
monotherapy to vancomycin plus ceftazidime
Table 1. In-vitro antimicrobial activity of ceftobiprole against clinically important Gram-positive and Gram-negative
pathogens
Species (number of isolates tested)
MIC (mg ⁄L)
Reference50% 90% Range
Staphylococcus aureus, oxacillin-susceptible (50) 0.5 0.5 0.25–2 [26]
S. aureus, oxacillin-resistant (96) 1 2 0.12–2 [26]
Staphylococci, coagulase-negative, oxacillin-susceptible (26) 0.12 0.25 £0.015–1 [26]
Staphylococci, coagulase-negative, oxacillin-resistant (90) 1 2 £0.015–4 [26]
Enterococcus faecalis (62) 0.5 4 0.12–>32 [26]
Enterococcus faecium (51a) >32 >32 0.25–>32 [26]
Streptococcus pneumoniae, penicillin-resistant 0.25 0.25 £0.015–1 [26]
b-Haemolytic streptococci (103) £0.015 £0.015 £0.015–0.06 [26]
Acinetobacter baumannii (10) 2 16 0.5–>64 [60]
P. aeruginosa (23)
P. aeruginosa (15)
2
8
8
32
0.12–16
0.25–64
[26]
[60]
aIncluded 25 vancomycin-resistant strains.
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combination therapy for clinical cure and clinical
relapse rates. Non-inferiority of ceftobiprole to the
combination comparator regimen was also shown
for microbiological eradication and relapse rates.
Sub-analysis of patients with microbiologically
conﬁrmed S. aureus infection showed that clinical
cure rates with ceftobiprole for MRSA and MSSA
were similar to those seen for vancomycin plus
ceftazidime. Similarly, clinical cure rates for
patients with conﬁrmed involvement of Pseudo-
monas aeruginosa and other Gram-negative patho-
gens were comparable for patients receiving
ceftobiprole and those receiving the combination
comparator regimen [62].
Sub-analysis of ﬁndings for patients with dia-
betic foot infection, which are particularly difﬁ-
cult-to-treat cSSSIs because of deﬁciencies in host
immunological responses and poor vascularisa-
tion [63], were comparable for patients receiving
ceftobiprole and those receiving vancomycin plus
ceftazidime (45th IDSA, abstract 1086).
Phase III clinical trials of ceftobiprole for the
treatment of pneumonia have recently been com-
pleted, and data are expected to become available
in 2008 (www.clinicaltrials.gov/ct2/results?term=
ceftobiprole).
CONCLUSION
S. aureus is a major cause of life-threatening
infections in hospital and community settings.
The acquisition of genes encoding PBP2a has
resulted in the emergence of MRSA, which is now
a global health concern. Vancomycin has been the
standard hospital treatment for the past 40 years,
but clinical isolates of S. aureus with decreased
susceptibility to vancomycin have been reported
at healthcare institutions around the world.
Strategies to develop new agents to overcome
the challenge of MRSA have called upon our
understanding of the mechanisms responsible for
antimicrobial resistance. Several agents have been
recently approved for the treatment of serious
Gram-positive infections, including new protein
synthesis inhibitors and a membrane-active
lipopeptide. Agents in development include
two glycopeptides that inhibit transpeptidase
and transglycosylase, and novel investigational
cephalosporins and carbapenems, including
ceftobiprole, that target low-b-lactam-afﬁnity
PBP2a. Ceftobiprole has demonstrated a broad
spectrum of activity against clinically important
Gram-negative and Gram-positive pathogens,
including MRSA. This spectrum of activity is
wider than that of other cephalosporins such as
cefepime and ceftriaxone. In phase III clinical
trials, ceftobiprole was as effective as vancomycin
for the treatment of Gram-positive cSSSIs, and as
effective as the combination of vancomycin and
ceftazidime for the treatment of Gram-positive
and Gram-negative cSSSIs.
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